Clinical Trials Directory

Trials / Completed

CompletedNCT03836092

ECGI in Patients With Persistent Atrial Fibrillation

Identification of AF Triggers, Initiators and Perpetuators by Electro Cardio-Graphic Imaging (ECGI) in Patients With Persistent Atrial Fibrillation

Status
Completed
Phase
Study type
Observational
Enrollment
50 (actual)
Sponsor
Pacific Rim Electrophysiology Research Institute · Academic / Other
Sex
All
Age
18 Years – 85 Years
Healthy volunteers
Not accepted

Summary

To determine the values and limitations of ECGI in guiding ablation and risk stratification in patients with persistent atrial fibrillation.

Detailed description

The patient population will include symptomatic persistent AF patients (N=50). The total of fifty patients will be studied to determine: * The values and limitations of ECGI in identifying atrial fibrillation (AF) triggers, AF initiators and AF perpetuators as targets sites for catheter ablations in patients with persistent AF. * The mechanisms of residual atrial tachycardia/flutter (Res-AT/AFl) after AF substrate ablations by targeting complex fractionated atrial electrograms (CFAE). * If there is a relationship between primary CFAE sites and driver sites or other distinct patterns from the ECGI mapping system. * The rate of AF termination to sinus rhythm after ablation at target sites identified by ECGI

Conditions

Interventions

TypeNameDescription
PROCEDURERadiofrequency ablationRF applications were delivered with a maximal temperature of 43°C at the catheter tip (SmartTouch Navistar Thermocool catheter) and at the power between 25-50 watts. The primary end points during RF ablation were either complete elimination of areas with CFAE or conversion of AF to normal sinus rhythm (SR). When areas with CFAE were completely eliminated but the atrial arrhythmias persisted (organized atrial flutter or atrial tachycardia), they were subsequently mapped and ablated (occasionally in conjunction with ibutilide, 1 - 2 mgs intravenously over 10 minutes).

Timeline

Start date
2018-02-23
Primary completion
2022-01-01
Completion
2022-04-01
First posted
2019-02-11
Last updated
2022-04-12

Locations

1 site across 1 country: Thailand

Source: ClinicalTrials.gov record NCT03836092. Inclusion in this directory is not an endorsement.